Articles

Videos

Podcasts

Clinical Role

Repotrectinib awarded breakthrough therapy designation for patients with ROS1-positive metastatic non–small cell lung cancer previously treated with a ROS1 tyrosine kinase inhibitor and who were not previously administered platinum-based chemotherapy.

FDA Grants Breakthrough Therapy Designation to Repotrectinib for ROS1-Positive Metastatic NSCLC  

The SKYSCRAPER-01 trial evaluating the drug plus Tecentriq demonstrates that it did not meet its co-primary endpoint of progression-free survival.

Study Results Show Genentech’s Tiragolumab Did Not Meet Primary Endpoints

They should consider many factors and use clear guidance on predicting phenotypes from genotypes to intervene optimally based on specific drug-gene interactions.

Pharmacists Play Role in Pharmacogenomics Clinical Services

Doug Long, vice president, Industry Relations, IQVIA, discusses notable trends reshaping specialty pharmaceutical channels and the impact of these developments on the role of the pharmacist in the health care team.

Assessing Specialty Pharmaceutical Trends Reshaping the Field for the Future

Vosevi is a fixed-dose combination for the treatment of hepatitis C virus.

Daily Medication Pearl: Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) for Hepatitis C

Joel Wayment, vice president of operations for 3PL Services at Cardinal Health, discusses how the pharmaceutical supply chain currently manages the transport of CAR T products to sites of administration.

Solutions to Facilitate Ease in Distribution of CAR T-Cell Therapies

Ray Tancredi, divisional vice president of Specialty Pharmacy, Development & Brand Rx/Vaccine Purchasing at Walgreens, discusses blockbuster drugs in the oncology space that have been approved this year or may be hitting the market soon.

Overview of Blockbuster Drugs in Oncology Approved in 2022, in the Pipeline for Approval in 2023

Tracy Russell, senior director, State Government Affairs at CoverMyMeds, discusses state and federal legislation that may be impacting the future of specialty pharmacies and the patient care they deliver.

State, Federal Legislation Impacting the Future of Specialty Pharmacies

Imposter syndrome is a phenomenon that affects self-confidence, significantly limiting the effectiveness of professionals affected by it.

How to Overcome Imposter Syndrome in Pharmacy

An international phase 1/2 clinical trial is ongoing for the treatment for individuals with relapsed or refectory acute myeloid leukemia with FLT3 mutation.

FDA Grants Fast Track Designation to Aptose’s HM43239 for Acute Myeloid Leukemia

® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.